INTRODUCTION
Thyroid cancer is the most prevalent endocrine malignancy in humans [1] , and the incidence of this type of cancer is rapidly increasing. The increase of thyroid cancer is so distinct in Korea that thyroid cancer has become the most common malignancy in Korean women according to a 2005 statistical report by the National Health Insurance Corporation of Korea. This is presumably due to the fact that papillary thyroid microcarcinoma is frequently detected as a result of the broad use of ultrasonography combined with fine needle aspiration cytology [2] . Consequently, the proportion of papillary thyroid carcinoma (PTC) among thyroid cancers is growing and is now an explanation for more than 90% of all thyroid cases.
Significant progress in the understanding of genetic events in PTC has been achieved over the past several decades. The RET proto-oncogene, which is rearranged thesurgery.or.kr during transfection, is located on chromosome 10q11. 2 and was first isolated in 1985 and was shown to be activated by a DNA rearrangement [3] . RET encodes a single-pass transmembrane tyrosine kinase that functions as the receptor tyrosine kinase for the growth factors of the glial cell line-derived neurotropic factor family [4] . In PTC, genomic rearrangements juxtapose the RET kinase and COOH-terminus encoding domains to unrelated genes, which thereby creates dominantly transforming oncogenes called RET/PTC rearrangements [5] . RET/PTC1 and RET/PTC3 account for more than 90% of all rearrangements and are hence, by far, the most frequent variants [6, 7] . These variants result from the fusion of RET to the coiled-coil domain containing gene 6 (CCDC6, formerly called H4/D10S170) or to the nuclear receptor coactivator gene 4 (NcoA4, formerly called RET fused gene/ELE1/ androgen receptor activator 70) [6, 7] .
A somatic point mutation in the BRAF gene has recently been identified as the most common genetic event in PTC [8] . The BRAF gene encodes a cytoplasmic serine/threonine kinase that is regulated by binding with RAS. Almost all of the BRAF point mutations found in PTC are a thymine-to-adenine transversion that occurs at nucleotide position 1796, which results in a valine-to-glutamate substitution at residue 599 (V599E) [9] . The V599E mutation is believed to mimic the phosphorylation in the activation segment as a result of the insertion of an acidic residue close to a site of regulated phosphorylation at serine 598 [10] . RAS point mutations are infrequent in PTC and are restricted to aggressive subtypes and to the follicular variant (FV) of PTC [11] . Despite the known linkage between these oncogenes and PTC, little is known about the molecular mechanisms that control the establishment, maintenance and progression of the PTC neoplastic phenotype.
Osteopontin (OPN), a secreted noncollagenous, sialicacid-rich, chemokine-like protein is recently receiving attention to give a clue to it. OPN is also known as a member of the small integrin binding ligand N-linked glycoprotein family with multifunctional properties in cell migration and cell survival. Previous researches have elucidated that OPN is up-regulated in a variety of cancers, such as breast, gastric, and colorectal cancers and in some highly metastatic cancer cell lines [12, 13] . In a recent study, OPN was found to be overexpressed in human PTCs, and the prevalence and intensity of OPN staining were correlated with aggressive features [14] , which suggests that OPN is one of the end products of the RET-RAS-BRAF-MAPK oncogenic cascade in PTCs. However, its direct correlation with somatic mutations was not examined.
This study was designed to evaluate the relationships between the degree of OPN expression in human PTC specimens, and the BRAF mutation and clinicopathologic variables. We expected it would serve practical hints on understanding of the RET-RAS-BRAF-MAPK linear signaling cascade of thyroid cancer cells.
METHODS

Tumor samples
Fifty-six snap-frozen thyroid tumor samples, including those of 49 PTCs, four follicular adenomas, two follicular carcinomas, and one Hürthle cell adenoma, were studied.
All of the analyzed specimens were sampled from primary tumors treated surgically at the Department of Surgery of the Seoul National University Hospital in Korea. All of the specimens were snap-frozen immediately after collection and stored at -80°C until use. Each patient signed an informed consent form prior to their surgical procedure, in which they approved the collection of fresh thyroid samples to be used for medical research.
After the initial review of selected cases, all of the glass slides of these samples were microscopically reexamined by a pathologist with a special interest in thyroid neoplasia. PTC was subclassified as classic papillary carcinoma or as a distinct histologic variant [15] based on the following criteria: FV, more than two-thirds of the tumor has follicular architecture with no well-formed papillae found; tall cell variant, more than 50% of tumor cells are twice as tall as they are wide. 
RNA extraction and reverse transcription
RNA extraction from the snap-frozen specimens was 
Genetic analysis
Specific primer pairs for the OPN gene were used to create gene-specific PCR amplicons using the reverse-transcribed product (Table 1 ). The levels of the housekeeping 
Statistical analysis
The association of OPN mRNA expression with multi- Each product of reverse transcription-polymerase chain reaction of OPN mRNA was loaded onto a 1.5% agarose gel that was stained with ethidium bromide (0.5 μg/mL). MyImager 1000 Image Analysis System was used for the quantification of each band. OPN mRNA expression of each sample was recorded as the fold increase with respect to the expression of the housekeeping GAPDH gene. CP, classic papillary type of papillary thyroid carcinoma; FV, follicular variant of papillary thyroid carcinoma; FA, follicular adenoma.
ver. 13.0 (SPSS Inc., Chicago, IL, USA).
RESULTS
Molecular genetic analysis
We calculated the OPN mRNA expression level as the fold increase with respect to the expression of the housekeeping GAPDH gene (Fig. 1) . OPN mRNA was significantly overexpressed in the PTCs, with respect to the other thyroid tumors including follicular adenomas, follicular carcinomas and Hürthle cell adenoma (P = 0.011) ( Table 2 ). Since the OPN expression level of the Hürthle cell adenoma was exceptionally high, the OPN overexpression in PTCs was more obvious compared to follicular neoplasms alone (P = 0.002) ( Table 2) .
A pathologic review subdivided the PTCs into three histologic subtypes, classic papillary (n = 39), FV-PTC (n = 8), and tall cell variant PTC (n = 2). The mean OPN expression level of the FV-PTCs was markedly lower than that of the other subtypes (P = 0.024) ( Table 3 ). The nonparametric Kruskal-Wallis test also showed that significant differences of OPN expression level exist among these three histologic subtypes (P = 0.002).
A search of BRAF mutations in PTCs showed the presence of a mutation of exon 15 in 37 of 46 PTCs (80.4%) ( Table 3 ). All of the mutations observed were the same missense T to A transversion at nucleotide 1796, which results in the substitution of a valine to glutamate at residue 599 (Fig. 2) . None of the seven non-PTC neoplasms had a mutation in exon 15. The frequency of the BRAF V599E mutation of each histologic PTC subtype, which all showed a tendency for similar influence on OPN expression, showed that FV-PTCs had the lowest frequency of the BRAF V599E mutation, but this was not statistically significant (P = 0.134).
Among the clinicopathologic variables studied, the absence of lymph node metastasis was significantly correlated with FV-PTC (not shown in table) (P = 0.006).
Genetico-clinicopathologic association analysis
To disclose whether OPN expression has any relevance in PTC phenotypes, we compared OPN mRNA expression levels among the PTCs with different clinicopathologic features ( Table 4 One-way analysis of variance. OPN exerts biological effects by mainly binding two types of cell surface receptors, which are CD44v6 and av-containing integrins [16] . Integrin or CD44-bound OPN activates the phosphoinositide 3-kinase (PI3-K)-Akt signaling pathways in murine pro-B-cell cell lines [17] , breast cancer cells [18] , and prostate cancer cells [19] . Akt is a serine/threonine kinase and regulates cell cycle progression, growth-factor-mediated cell survival, cell migration and anchorage-independent growth of tumor cells [20] . When it comes to thyroid carcinoma, there have been two remarkable studies in regard to OPN. Castellone et al. [21] found that OPN was the most strongly upregulated gene Although one specimen's result has little significance, we can infer that the disruptive mutations of mitochondrial DNA that is reported to be present in 26% of all Hürthle cell tumors [22] may have some role in the OPN expression that was observed in our study.
Our data demonstrate that FV-PTC is negatively correlated with OPN expression, and this is identical to the results of a previous study [14] . On the molecular level, FV-PTC is characterized by a high prevalence of RAS mutations and a low prevalence of RET/PTC rearrangement or the BRAF mutation [11, 23] . In two large series of FV-PTC, a significantly higher frequency of total or partial encapsulation and a lower rate of lymph node metastases were found in FV tumors in comparison with classic papillary carcinomas, and the prognosis of this type of cancer is similar to or better than those of classic PTCs [24, 25] . In the present study, we could not identify a significant tendency tions, the BRAF mutation is the most common somatic mutation in PTCs, and its prevalence was reported as 29 to 69% [26] . This is especially important in Korea since the prevalence of PTCs is very high (83%) in Koreans [27] . A high prevalence of the BRAF mutation in PTCs (80.4%) was observed in our study, and all identified BRAF exon 15
mutations in the present study were BRAF
V599E
, which is similar to the findings of previous studies. There has been controversy regarding the significance of the BRAF mutation as a prognostic factor, but recent studies with relatively large sample sizes support that the BRAF mutation is associated with poorer clinicopathological outcomes [28] and independently predicts recurrence [29] . We observed, in the present study, a significant association between the BRAF mutation and advanced N stage, but did not find association between the BRAF mutation and any other aggressive feature of PTC. This is probably due to the high prevalence of the BRAF mutation in our study.
We also showed that the OPN mRNA expression level was significantly high in human PTC specimens with the BRAF V599E mutation and aggressive clinicopathologic features. This result suggests that OPN can be a common product of the RET/PTC-RAS-BRAF-MAPK pathway or a result of the BRAF mutation, and that it plays a pivotal role in tumor progression and metastasis of PTC cells. This finding is also in concordance with the reports that OPN bound with integrin or CD44 activates the PI3-K-Akt signaling pathways, and increased Akt stimulates cell survival and migration in other types of cancer cells [17] [18] [19] . We emphasize that the illustrated correlation between OPN mRNA expression level and BRAF mutation will have importance in geographic areas where the prevalence of BRAF mutation in PTCs is relatively high, like in Korea, and that, if a better understanding of OPN can be achieved in future studies, then OPN might be used as a useful diagnostic tumor maker and therapeutic target of PTCs.
In conclusion, OPN is overexpressed in PTCs with BRAF mutations, aggressive histologic subtypes, and lymph node metastasis, and this indicates that it plays a thesurgery.or.kr crucial role in tumorigenesis and the progression of PTC.
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